| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 7, 2018 | PAHC Phibro Animal Health Corp | Bendheim Jack52 | President And CEO | Sell | 36,000 | $39.01 | $1,404,246.22 | -12.2% | |
| Mar 6, 2018 | BHC Bausch Health Companies Inc. | Paulson John52 | Director | Sell | 7,066,629 | $15.40 | $108,826,086.60 | -33.9% | |
| Mar 6, 2018 | BHC Bausch Health Companies Inc. | Paulson John52 | Director | Buy | 7,066,629 | $15.40 | $108,826,086.60 | +51.3% | |
| Mar 6, 2018 | AYTU Aytu Biopharma, Inc | Disbrow Joshua R.57 | Chief Executive Officer | Buy | 226,105 | $0.45 | $101,747.25 | +85.4% | |
| Mar 6, 2018 | AYTU Aytu Biopharma, Inc | Disbrow Jarrett | Chief Operating Officer | Buy | 226,105 | $0.45 | $101,747.25 | +106.0% | |
| Mar 6, 2018 | AYTU Aytu Biopharma, Inc | Green David A | Chief Financial Officer | Buy | 66,600 | $0.45 | $29,970.00 | +88.8% | |
| Mar 6, 2018 | EGRX Eagle Pharmaceuticals, Inc. | Flaum Sander A | Director | Sell | 2,340 | $53.94 | $126,219.60 | -17.1% | |
| Mar 6, 2018 | PAHC Phibro Animal Health Corp | Bendheim Daniel M | Exec. VP, Corporate Strategy | Sell | 3,960 | $40.06 | $158,646.60 | -100% | |
| Mar 5, 2018 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 1,979 | $88.47 | $175,089.65 | -11.0% | |
| Mar 5, 2018 | ANIP Ani Pharmaceuticals Inc | Marken James G.47 | SVP Ops &Prod Dev | Sell | 4,177 | $61.92 | $258,639.84 | -6.0% | |
| Mar 5, 2018 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 23,650 | $90.00 | $2,128,500.00 | -23.1% | |
| Mar 5, 2018 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 75,873 | $90.00 | $6,828,570.00 | -21.8% | |
| Mar 5, 2018 | PRGO Perrigo Co Plc | Roehrhoff Uwe | CEO | Buy | 7,500 | $81.85 | $613,862.59 | +153.1% | |
| Mar 5, 2018 | IRWD Ironwood Pharmaceuticals Inc | McHugh Julie53 | Director | Sell | 1,500 | $14.06 | $21,090.00 | -1.9% | |
| Mar 5, 2018 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 2,000 | $14.05 | $28,100.00 | -6.4% | |
| Mar 5, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 1,108 | $19.28 | $21,362.24 | -100% | |
| Mar 5, 2018 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 705 | $19.38 | $13,662.90 | -33.7% | |
| Mar 5, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 773 | $19.38 | $14,980.74 | -100% | |
| Mar 1, 2018 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 860 | $76.50 | $65,790.00 | -34.4% | |
| Mar 1, 2018 | ANIP Ani Pharmaceuticals Inc | Schrepfer Robert W | SVP - New Bus Dev &Spec Sales | Sell | 28,652 | $61.66 | $1,766,770.84 | -24.6% | |
| Mar 1, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $57.04 | $57,040.00 | -11.1% | |
| Mar 1, 2018 | CANN Trees Corp (colorado) | Frichtel Robert Lawrence | Chief Executive Officer | Sell | 50,000 | $3.45 | $172,304.79 | -1.1% | |
| Mar 1, 2018 | ANIP Ani Pharmaceuticals Inc | Przybyl Arthur | President And CEO | Sell | 23,986 | $61.23 | $1,468,694.54 | -3.6% | |
| Mar 1, 2018 | PAHC Phibro Animal Health Corp | Bfi Co., LLC | 10% Owner | Sell | 36,000 | $38.35 | $1,380,720.00 | -20.0% | |
| Mar 1, 2018 | EBS Emergent Biosolutions Inc. | Havey Adam | EVP, Business Operations | Sell | 1,898 | $49.50 | $93,951.00 | -5.4% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.